Friedrich Miescher Institute for Biomedical Research (Part of the Novartis Research Foundation), Basel, Switzerland.
Breast Cancer Res. 2009;11(3):R32. doi: 10.1186/bcr2317. Epub 2009 May 27.
In breast cancer, deregulation of the WNT signaling pathway occurs by autocrine mechanisms. WNT ligands and Frizzled receptors are coexpressed in primary breast tumors and cancer cell lines. Moreover, many breast tumors show hypermethylation of the secreted Frizzled-related protein 1 (sFRP1) promoter region, causing low expression of this WNT antagonist. We have previously shown that the WNT pathway influences proliferation of breast cancer cell lines via activation of canonical signaling and epidermal growth factor receptor transactivation, and that interference with WNT signaling reduces proliferation. Here we examine the role of WNT signaling in breast tumor cell migration and on xenograft outgrowth.
The breast cancer cell line MDA-MB-231 was used to study WNT signaling. We examined the effects of activating or blocking the WNT pathway on cell motility by treatment with WNT ligands or by ectopic sFPR1 expression, respectively. The ability of sFRP1-expressing MDA-MB-231 cells to grow as xenografts was also tested. Microarray analyses were carried out to identify targets with roles in MDA-MB-231/sFRP1 tumor growth inhibition.
We show that WNT stimulates the migratory ability of MDA-MB-231 cells. Furthermore, ectopic expression of sFRP1 in MDA-MB-231 cells blocks canonical WNT signaling and decreases their migratory potential. Moreover, the ability of MDA-MB-231/sFRP1-expressing cells to grow as xenografts in mammary glands and to form lung metastases is dramatically impaired. Microarray analyses led to the identification of two genes, CCND1 and CDKN1A, whose expression level is selectively altered in vivo in sFRP1-expressing tumors. The encoded proteins cyclin D1 and p21Cip1 were downregulated and upregulated, respectively, in sFRP1-expressing tumors, suggesting that they are downstream mediators of WNT signaling.
Our results show that the WNT pathway influences multiple biological properties of MDA-MB-231 breast cancer cells. WNT stimulates tumor cell motility; conversely sFRP1-mediated WNT pathway blockade reduces motility. Moreover, ectopic sFRP1 expression in MDA-MB-231 cells has a strong negative impact on tumor outgrowth and blocked lung metastases. These results suggest that interference with WNT signaling using sFRP1 to block the ligand- receptor interaction may be a valid therapeutic approach in breast cancer.
在乳腺癌中,WNT 信号通路的失调通过自分泌机制发生。WNT 配体和卷曲受体在原发性乳腺癌肿瘤和癌细胞系中共同表达。此外,许多乳腺癌表现出分泌卷曲相关蛋白 1(sFRP1)启动子区域的高甲基化,导致这种 WNT 拮抗剂的低表达。我们之前已经表明,WNT 途径通过激活经典信号和表皮生长因子受体的反式激活来影响乳腺癌细胞系的增殖,并且干扰 WNT 信号会降低增殖。在这里,我们研究了 WNT 信号在乳腺癌细胞迁移和异种移植物生长中的作用。
使用乳腺癌细胞系 MDA-MB-231 研究 WNT 信号。我们通过用 WNT 配体处理或通过异位表达 sFPR1 分别研究激活或阻断 WNT 途径对细胞迁移的影响。还测试了表达 sFRP1 的 MDA-MB-231 细胞作为异种移植物生长的能力。进行了微阵列分析以鉴定在 MDA-MB-231/sFRP1 肿瘤生长抑制中起作用的靶标。
我们表明 WNT 刺激 MDA-MB-231 细胞的迁移能力。此外,MDA-MB-231 细胞中 sFRP1 的异位表达阻断了经典的 WNT 信号通路,并降低了它们的迁移潜力。此外,表达 MDA-MB-231/sFRP1 的细胞作为异种移植物在乳腺中生长和形成肺转移的能力显著受损。微阵列分析导致鉴定出两个基因,CCND1 和 CDKN1A,其表达水平在体内选择性地改变 sFRP1 表达的肿瘤。编码蛋白 cyclin D1 和 p21Cip1 在 sFRP1 表达的肿瘤中分别下调和上调,表明它们是 WNT 信号的下游介质。
我们的结果表明,WNT 途径影响 MDA-MB-231 乳腺癌细胞的多种生物学特性。WNT 刺激肿瘤细胞迁移;相反,sFRP1 介导的 WNT 途径阻断减少了迁移。此外,MDA-MB-231 细胞中 sFRP1 的异位表达对肿瘤生长有很强的负向影响,并阻断了肺转移。这些结果表明,使用 sFRP1 阻断配体-受体相互作用来干扰 WNT 信号可能是乳腺癌的一种有效治疗方法。